Does prenatal exposure to sertraline increase the risk of autism spectrum disorder in the offspring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No Causal Link Between Prenatal Sertraline Exposure and Autism

The best available evidence indicates that prenatal sertraline (or other antidepressant) exposure does not causally increase the risk of autism spectrum disorder in offspring—the observed associations in crude analyses are explained by confounding factors, particularly maternal depression severity, genetic factors, and shared familial characteristics.

Key Evidence from Rigorous Study Designs

The 2019 comprehensive guideline review in the Journal of Child Psychology and Psychiatry 1 provides the most authoritative analysis using multiple methodological approaches to address confounding:

Sibling Comparison Studies (Strongest Evidence)

  • Meta-analysis of sibling comparisons showed no increased risk: pooled adjusted relative risk of 0.9 (95% CI: 0.8–1.2) 1
  • Two large individual studies found no association:
    • Sorensen et al.: aHR 1.1 (95% CI: 0.5–2.3) in 668,468 offspring 1
    • Sujan et al.: aHR 0.8 (95% CI: 0.6–1.1) in 1,580,629 offspring 1
  • This design controls for shared genetic and environmental factors between siblings, making it far superior to population-based comparisons

Timing of Exposure Analysis

  • Antidepressant use before pregnancy showed similar magnitude associations with ASD as use during pregnancy 1
  • If the medication itself caused autism, pre-pregnancy exposure (when no fetal exposure occurs) should show no association
  • This pattern strongly suggests confounding by indication rather than causal medication effects

Paternal Comparison Studies

  • Paternal antidepressant use during pregnancy (which cannot cause fetal drug exposure) showed associations with offspring ASD 1
  • Meta-analysis: pooled aRR of 1.3 (95% CI: 1.1–1.5) for paternal use 1
  • This indicates familial confounding factors (genetics, shared environment) rather than direct medication effects

Active Comparator Design

  • Comparing SSRI exposure to non-SSRI antidepressants showed no increased risk: OR 1.1 (95% CI: 0.7–2.0) 1
  • If SSRIs specifically caused autism, they should show higher risk than other antidepressants

Recent Confirmatory Studies

The 2024 Taiwan nationwide study 2 with 2.3 million children found:

  • Population-wide analysis initially showed associations
  • Sibling comparison analysis showed NO association:
    • First trimester HR: 1.04 (95% CI: 0.76-1.42)
    • Second trimester HR: 0.96 (95% CI: 0.62-1.50)
    • Third trimester HR: 0.69 (95% CI: 0.32-1.48)
  • Paternal exposure and pre/post-pregnancy exposure also showed associations, confirming confounding

The 2017 Canadian study 3 using high-dimensional propensity scores found:

  • Crude analysis showed HR 2.16 (95% CI: 1.64-2.86)
  • After rigorous adjustment: HR 1.61 (95% CI: 0.997-2.59)—not significant
  • Sibling comparison: HR 1.60 (95% CI: 0.69-3.74)—not significant

Understanding the Confounding

The 2018 UK study 4 clarified the true risk factor:

  • Maternal depression itself (treated or untreated) increases ASD risk
  • Treated depression: RR 1.72 (95% CI: 1.54-1.93)
  • Untreated depression: RR 1.50 (95% CI: 1.28-1.75)
  • Antidepressants for non-psychiatric indications: RR 0.73 (95% CI: 0.41-1.29)—no increased risk
  • Risk increased with depression severity, not with antidepressant treatment

FDA Label Context

The sertraline FDA label 5 notes:

  • Animal studies at 4× human doses showed no teratogenicity
  • Neonatal complications can occur (withdrawal/adaptation syndrome)
  • No specific mention of autism risk
  • Emphasizes weighing untreated depression risks against medication risks

Clinical Bottom Line

Do not withhold or discontinue sertraline in pregnant women based on autism concerns. The evidence demonstrates:

  1. Untreated maternal depression carries its own neurodevelopmental risks 4
  2. The association between antidepressants and autism disappears when properly controlling for confounding 1, 2, 3
  3. Multiple independent methodological approaches converge on the same conclusion: no causal effect 1

Common Pitfalls to Avoid

  • Don't rely on crude population-based studies that show associations—these are confounded by maternal psychiatric illness, genetics, and socioeconomic factors
  • Don't assume correlation equals causation—the pre-pregnancy and paternal exposure data definitively rule out direct medication effects
  • Don't underestimate the risks of untreated maternal depression on both maternal and fetal outcomes

Decision Framework

When counseling pregnant women on sertraline:

  • Acknowledge that crude studies show associations but explain they are due to confounding
  • Emphasize that the highest-quality evidence (sibling comparisons, timing analyses) shows no causal link
  • Discuss the established risks of untreated depression during pregnancy
  • Continue sertraline if clinically indicated for maternal mental health

The 2019 guideline 1 explicitly states: "The findings summarized in this review may help women and their doctors make informed decisions about antidepressant use during pregnancy by providing reassurance that use of these medications during pregnancy is unlikely to substantially increase the risk of ASD."

References

Related Questions

What medications are used to manage symptoms associated with autism spectrum disorder?
What are the two core domains in the DSM‑5 required to diagnose autism spectrum disorder?
In a 33‑year‑old woman with depression treated with sertraline 150 mg who is experiencing restlessness and anxiety after a new diagnosis of Attention‑Deficit/Hyperactivity Disorder and is taking quetiapine (Seroquel) 25 mg for sleep, how should her medication regimen be managed?
In a 74-year-old female with depression currently taking sertraline 100 mg daily who is experiencing worsening symptoms, what augmentation medication can be added?
What is the best benzodiazepine for a 27-year-old male with autism undergoing dental treatment for cavities?
What is the appropriate dosing of acamprosate for adult patients, and how should renal impairment affect dosing and contraindications?
What treatments are recommended for temporomandibular joint disorder that also address anxiety, aside from nortriptyline?
Please explain in plain language the lumbar spine MRI findings of multilevel degenerative changes, grade 1 retrolisthesis of L5 on S1, disc desiccation, and disc bulges at L3‑L4 and L5‑S1 causing foraminal narrowing in a patient with low back pain.
Do you use the clozapine or norclozapine plasma concentration to assess efficacy?
Is prednisone safe for renal function?
What clinical, laboratory, and imaging signs indicate that a patient with a prior knee joint infection can safely discontinue long‑term antibiotic therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.